Overview
Kernicterus, also called **chronic bilirubin encephalopathy**, is a rare but permanent form of brain damage that occurs when high levels of unconjugated bilirubin cross the immature blood‑brain barrier of a newborn and deposit in specific brain regions (especially the basal ganglia, subthalamic nuclei, hippocampus, and cerebellum). The damage leads to a spectrum of neurological deficits that can be life‑long.
- Who it affects: Primarily newborn infants, most often within the first week of life. Although the condition is almost exclusively seen in premature or low‑birth‑weight infants, term infants can be affected if bilirubin rises rapidly.
- Prevalence: In high‑income countries, kernicterus is now uncommon, with an estimated incidence of < 0.5 cases per 10,000 live births thanks to universal newborn screening and phototherapy protocols. In low‑ and middle‑income countries, where access to timely treatment is limited, the incidence can be 10–30 times higher (WHO, 2022).
Symptoms
The clinical picture evolves in three phases: acute bilirubin‑induced neurologic dysfunction, a silent “intermediate” period, and chronic neurologic sequelae (kernicterus).
Acute Phase (first 1–3 days)
- Hypotonia or “floppiness” – decreased muscle tone, especially in the trunk.
- Feeding difficulty – poor suck, lethargy, or prolonged sleeping.
- High‑pitch cry or “cry of distress” – indicative of brain irritation.
- Seizures – may be focal or generalized.
- Arousal changes – difficulty waking for feeds or responding to stimuli.
Intermediate Phase (days‑to‑weeks after bilirubin falls)
- Infants may appear relatively normal; however, subtle motor abnormalities can begin to emerge.
Chronic Phase (months‑years later)
- Movement disorders:
- Spasticity or rigid limb posturing.
- Athetosis (slow, writhing movements).
- Extrapyramidal signs such as dystonia.
- Auditory dysfunction: Bilateral sensorineural hearing loss in 30–50 % of affected children (Mayo Clinic, 2023).
- Ophthalmologic findings: Gaze palsy, abnormal eye movements, or optic atrophy.
- Cognitive impairment: Ranges from mild learning difficulties to severe intellectual disability.
- Dental enamel defects – “yellow-brown” discoloration of teeth.
- Behavioral issues: Hyperactivity, poor impulse control, and social interaction challenges.
Causes and Risk Factors
Kernicterus is not a disease itself but the end result of **severe hyperbilirubinemia**. Unconjugated bilirubin is neurotoxic when serum levels exceed the brain's protective capacity.
Primary Causes
- Hemolytic disease of the newborn (HDN): Most commonly due to ABO or Rh incompatibility.
- Genetic enzyme deficiencies: G6PD deficiency, hereditary spherocytosis, or Crigler‑Najjar type I (complete lack of UDP‑glucuronosyltransferase).
- Prematurity: Immature liver enzymes and a more permeable blood‑brain barrier.
- Breast‑feeding jaundice: Inadequate intake leading to dehydration and reduced bilirubin excretion.
- Breast‑milk jaundice: Substances in breast milk that inhibit bilirubin conjugation (often peaks at 2‑3 weeks).
- Sepsis or meningitis: Inflammatory cytokines impair hepatic bilirubin uptake.
- Acidosis, hypothermia, or significant hypoxia: Increase bilirubin‑brain permeability.
Risk Factors
- Gestational age < 37 weeks or birth weight < 2500 g.
- Family history of severe jaundice or enzyme deficiency.
- Male sex (studies show a 1.3‑fold higher risk).
- East Asian ancestry (higher prevalence of G6PD deficiency).
- Delayed first feeding or poor lactation support.
- Use of medications that displace bilirubin from albumin (e.g., sulfonamides, certain antibiotics).
Diagnosis
Early recognition is vital. Diagnosis combines clinical assessment with laboratory and imaging tools.
Clinical Assessment
- Physical exam focusing on skin/ scleral icterus, tone, reflexes, and level of consciousness.
- Documentation of feeding patterns, weight loss, and urine/stool color.
Laboratory Tests
- Serum total bilirubin (TB) and direct bilirubin: Levels > 20 mg/dL (340 µmol/L) in term infants, or > 15 mg/dL (255 µmol/L) in preterm infants, signal high risk (AAP guidelines, 2022).
- Blood‑type and Coombs test: Detects alloimmune hemolysis.
- Complete blood count (CBC) and reticulocyte count: Assess hemolysis.
- G6PD assay, liver function tests, and metabolic panels when indicated.
Neuro‑imaging & Ancillary Tests
- Transcranial ultrasound – can show basal ganglia echogenicity in severe cases.
- MRI (T1‑weighted) – characteristic hyperintensity in the globus pallidus and subthalamic nuclei, confirming bilirubin deposition.
- Auditory brainstem response (ABR) – baseline hearing screen; abnormal results are common after kernicterus.
- Electroencephalography (EEG) – may reveal seizure activity during the acute phase.
Scoring Systems
The **Bilirubin–Age‑Risk (BARK) score** and the **American Academy of Pediatrics (AAP) phototherapy thresholds** help determine when bilirubin levels become dangerous and when to intervene.
Treatment Options
Management focuses on **rapid removal of bilirubin** and preventing further neurotoxicity.
Acute Interventions
- Phototherapy: Blue‑light (460–490 nm) converts unconjugated bilirubin into water‑soluble isomers that are excreted without conjugation. Intensive double‑surface phototherapy is the first‑line treatment for bilirubin > 20 mg/dL in term infants.
- Exchange transfusion: Indicated when bilirubin exceeds the exchange‑transfusion threshold (≈ 25 mg/dL for term infants) or when neuro‑symptoms appear despite phototherapy. The procedure replaces the infant’s blood with donor blood, rapidly lowering bilirubin.
- IVIg (intravenous immunoglobulin): May be used in hemolytic disease due to ABO incompatibility to reduce hemolysis.
- Supportive care: Maintain normothermia, correct acidosis, ensure adequate hydration, and treat any underlying infection.
Long‑Term Management
- Hearing rehabilitation: Early cochlear implantation or hearing aids for sensorineural loss.
- Physical and occupational therapy: To improve motor function, reduce spasticity, and maximize independence.
- Speech and language therapy: Addresses feeding difficulties and communication delays.
- Educational support: Individualized Education Programs (IEPs) for learning disabilities.
- Pharmacologic agents for spasticity: Baclofen, tizanidine, or botulinum toxin injections as guided by a neurologist.
Living with Kernicterus (Chronic Bilirubin Encephalopathy)
While the brain injury is permanent, a multidisciplinary approach can improve quality of life.
Daily Management Tips
- Routine medical follow‑up: Neurology, audiology, ophthalmology, and developmental pediatrics visits every 3–6 months during early childhood, then annually.
- Positioning & mobility: Use supportive seating, adaptive walkers, or standers to prevent contractures.
- Skin care: Children with spasticity are prone to pressure sores; rotate positions every 2 hours.
- Nutrition: High‑calorie, protein‑rich diet; consider gastrostomy tube if oral intake is unsafe.
- Medication adherence: Keep a medication log for antispasmodics, seizure prophylaxis, or vitamin D supplementation (to counter reduced mobility).
- Family support: Connect with local support groups (e.g., Kernicterus Foundation) and counseling services to address caregiver stress.
Psychosocial Considerations
Children may experience frustration from communication barriers or social isolation. Early inclusion in early‑intervention programs and peer‑play groups fosters emotional development.
Prevention
Because kernicterus is preventable in the vast majority of cases, public‑health measures are essential.
- Universal newborn bilirubin screening: Transcutaneous bilirubinometry or serum measurement before discharge.
- Early and exclusive breastfeeding support: Assistance with latch, feeding frequency, and monitoring weight loss (no more than 7 % of birth weight in 24 hrs).
- Timely phototherapy: Follow AAP phototherapy guidelines; most hospitals have LED phototherapy units ready.
- Maternal education: Counsel about signs of jaundice, importance of feeding, and when to call the pediatrician.
- Screening for hemolytic disease: Maternal and infant blood typing, Coombs test, and G6PD screening in high‑risk populations.
- Avoid bilirubin‑displacing drugs: Use caution with sulfonamides, aspirin, or high‑protein parenteral nutrition in neonates.
- Quality improvement programs: Hospital policies that trigger a rapid response when bilirubin approaches the “high‑risk zone.”
Complications
If hyperbilirubinemia is not controlled, the following complications can arise:
- Permanent neurologic deficits: Movement disorders, cerebral palsy–like syndromes, and intellectual disability.
- Severe hearing loss: May require bilateral cochlear implants.
- Visual impairment: Nystagmus, strabismus, or optic atrophy.
- Epilepsy: Chronic seizure disorders develop in up to 20 % of affected children.
- Dental enamel hypoplasia: Cosmetic and functional concerns.
- Psychosocial impact: Lower educational attainment, increased need for special services, and caregiver burnout.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if your newborn shows any of the following signs:
- Rapidly rising or persistent jaundice (especially if the skin looks yellow beyond the abdomen or the whites of the eyes are deeply yellow).
- High‑pitched, inconsolable crying or a sudden change in cry quality.
- Lethargy, poor feeding, or inability to wake for feeds.
- Muscle stiffness, arching of the back, or floppy limbs.
- Seizure activity – eye‑rolling, stiffening, rhythmic jerking.
- Rapid breathing, bluish coloration around the lips or extremities.
These symptoms may indicate bilirubin levels that are high enough to threaten the brain. Prompt treatment can prevent permanent damage.
References
- American Academy of Pediatrics. Management of Hyperbilirubinemia in the Newborn Full-Term and Preterm Infants. Pediatrics. 2022;149(5):e2022057123.
- Mayo Clinic. Kernicterus. Last reviewed 2023. https://www.mayoclinic.org
- World Health Organization. Neonatal Jaundice: A Global Health Priority. WHO Guidelines, 2022.
- National Institutes of Health. Crigler‑Najjar Syndrome. Genetics Home Reference, 2023.
- Cleveland Clinic. Bilirubin and Jaundice in Newborns. 2023. https://my.clevelandclinic.org
- Olusanya BO, et al. Global burden of neonatal hearing loss. Eur J Pediatr. 2021;180(5):1747‑1758.